Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital

Introduction: We aimed to analyze the outcome in a series of women with primary advanced ovarian cancer in an Intermediate Volume Hospital where new surgical and chemotherapy treatments were implemented over a period of 14 years. Material and Methods: One hundred and twenty-seven women with stage IIIB-IV disease underwent primary (76.4%) or interval debulking surgery (23.6%). Fifty-seven were operated on from 2000 to 2005 (Group 1) and 70 from 2006 to 2014 (Group 2). Results: No gross residual disease was achieved in 51.5% and 43.3% of women who underwent primary and interval surgery, respectively. For no gross and < 1cm residual disease, median overall and progression-free survival were 94.7 vs. 60.6 months (p = 0.001) and 25.3 vs. 20.0 months, respectively (p = 0.02). The rate of no gross residual (36.8 to 60.0%) and 5-yr median overall survival (56.3 to 73.7 months) increased between 2000-2005 (Group 1) and from 2006 to 2014 (Group 2). On multivariate analysis, interval surgery, multiple peritoneal implants and residual disease were predictive of overall and progression-free survival. Conclusions: Survival after primary and interval debulking surgery progressively correlates with decrease in residual disease. Increasing rates of successful primary surgery are possible through standardization and adoption of best practices without increasing morbidity.

Ovarian cancer; Cytoreduction; Neoadjuvant chemotherapy; Bevacizumab; Hospital volume.

[1] du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I. and Pfisterer J.: “Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials”. Cancer, 2009, 115, 1234-1244.

[2] Elattar A., Bryant A., Winter-Roach B.A., Hatem M., Naik R.: “Optimal primary surgical treatment for advanced epithelial ovarian cancer”. Cochrane Database Syst. Rev., 2011, 2011, CD007565.

[3] Chang S., Hodeib M., Chang J., Bristow R.E.: “Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis”. Gynecol. Oncol., 2013, 130, 493- 498.

[4] Wallace S., Kumar A., Mc Gree M., Weaver A., Mariani A., Langstraat C., et al.: “Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible”. Gynecol. Oncol., 2017, 145, 21-26.

[5] Morrison J., Haldar K., Kehoe S., Lawrie T.A.: “Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer”. Cochrane Database Syst. Rev., 2012, 8, CD005343

[6] Timmermans M., van der Hel O., Sonke G.S., Van de Vijver K.K., van der Aa M.A., Kruitwagen R.F.: “The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer: a systematic review”. Gynecol. Oncol., 2019, 153, 445-451.

[7] Wright J.D., Huang Y., Melamed A., Tergas A.I., St. Clair C.M., Hou J. Y., et al.: “Potential consequences of minimum-volume standards for hospitals treating women with ovarian cancer”. Obstet. Gynecol., 2019, 133, 1109-1119.

[8] Chang S., Bristow R.E., Ryu H.: “Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer”. Ann. Surg. Oncol., 2012, 19, 4059-4067.

[9] Dindo D., Demartines N., Clavien P.: “Classification of surgical complications”. Ann. Surg., 2004, 240, 205-213.

[10] Winter W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P. G., et al.: “Prognostic factors for stage iii epithelial ovarian cancer: a gynecologic oncology group study”. J. Clin. Oncol., 2007, 25, 3621-3627.

[11] Chiva L. M., Castellanos T., Alonso S., Gonzalez-Martin A.: “Minimal Macroscopic Residual Disease (0.1–1 cm). Is It Still a Surgical Goal in Advanced Ovarian Cancer?”. Int. J. Gynecol. Cancer, 2016, 26, 906-911.

[12] Wright J.D., Chen L., Hou J.Y., Burke W.M., Tergas A.I., Ananth C. V., et al.: “Association of hospital volume and quality of care with survival for ovarian cancer”. Obstet. Gynecol., 2017, 130, 545-553.

[13] Harter P., Muallem Z.M., Buhrmann C., Lorenz D., Kaub C., Hils R., et al.: “Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer”. Gynecol. Oncol., 2011, 121, 615-619.

[14] Chi D.S., Eisenhauer E.L., Zivanovic O., Sonoda Y., Abu-Rustum N. R., Levine D.A., et al.: “Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm”. Gynecol. Oncol., 2009, 114, 26-31.

[15] du Bois A., Rochon J., Pfisterer J., Hoskins W. J.: “Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review”. Gynecol. Oncol., 2009, 112, 422-436.

[16] Bristow R.E., Palis B.E., Chi D.S., Cliby W.A.: “The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm”. Gynecol. Oncol., 2010, 118, 262-267.

[17] Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al.: “The addition of extensive up-per abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer”. Gynecol. Oncol., 2006, 103, 1083-1090.

[18] Horowitz N. S., Miller A., Rungruang B., Richard S. D., Rodriguez N., Bookman M. A., et al.: “Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients with Advanced-Stage Ovarian Cancer: An Analysis of GOG 182”. J. Clin. Oncol., 2015, 33, 937-943.

[19] Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al.: “Aggressive surgical effort and improved survival in advanced-stage ovarian cancer”. Obstet. Gynecol., 2006, 107, 77-85.

[20] Fotopoulou C., Sehouli J., Aletti G., Harter P., Mahner S., Querleu D., et al.: “Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a european perspective”. J. Clin. Oncol., 2017, 35, 587-590.

[21] Chiva L., Lapuente F., Castellanos T., Alonso S., Gonzalez-Martin A.: “What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?”. Ann. Surg. Oncol., 2016, 23, 1666-1673.

[22] Wright A.A., Bohlke K., Armstrong D.K., Bookman M.A., Cliby W. A., Coleman R.L., et al.: “Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and american society of clinical oncology clinical practice guideline”. J. Clin. Oncol., 2016, 34, 3460-3473.

[23] Chi D.S., Musa F., Dao F., Zivanovic O., Sonoda Y., Leitao M.M., et al.: “An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs. neoadjuvant chemotherapy (NACT)”. Gynecol. Oncol., 2012, 124, 10-14.

[24] Reuss A., du Bois A., Harter P., Fotopoulou C., Sehouli J., Aletti G., et al.: “TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)”. J. Gy-necol. Oncol., 2019, 29, 1327-1331.

[25] Tewari D., Java J.J., Salani R., Armstrong D.K., Markman M., Her-zog T., et al.: “Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study”. J. Clin. On-col., 2015, 33, 1460-1466.

[26] Jaaback K., Johnson N., Lawrie T.A.: “Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer”. Cochrane Database Syst. Rev., 2011, 2011, CD005340.

[27] Walker J.L., Brady M.F., Wenzel L., Fleming G.F., Huang H.Q., DiSilvestro P.A., et al.: ”Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: an NRG Oncology/Gynecologic Oncology Group Study”. J. Clin. Oncol., 2019, 37, 1380-1390.

[28] González Martín A., Oza A.M., Embleton A.C., Pfisterer J., Leder-mann J.A., Pujade-Lauraine E., et al.: “Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer”. Gynecol. Oncol., 2019, 152, 53-60.

[29] Tewari K.S., Burger R.A., Enserro D., Norquist B.M., Swisher E.M., Brady M.F., et al.: ”Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer”. J Clin Oncol, 2019, 37, 2317-2328.